Scancell (LON:SCLP) Trading 29.8% Higher – Should You Buy?

Shares of Scancell Holdings plc (LON:SCLPGet Free Report) traded up 29.8% during mid-day trading on Monday . The stock traded as high as GBX 11.49 ($0.15) and last traded at GBX 11 ($0.14). 10,149,031 shares changed hands during mid-day trading, an increase of 1,037% from the average session volume of 892,663 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Performance

The firm has a market cap of £113.93 million, a P/E ratio of -16.86 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The business’s 50-day simple moving average is GBX 8.43 and its 200 day simple moving average is GBX 10.88.

Scancell (LON:SCLPGet Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. As a group, equities analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

About Scancell

(Get Free Report)

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

Further Reading

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.